|
1.
|
Greillier L and Astoul P: Mesothelioma and
asbestos-related pleural diseases. Respiration. 76:1–15. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bueno R: Mesothelioma clinical
presentation. Chest. 116(Suppl 6): S444–S445. 1999. View Article : Google Scholar
|
|
3.
|
Fujimoto N, Aoe K, Gamba K, Kato K,
Yamazaki K and Kishimoto T: Clinical investigation of malignant
mesothelioma in Japan. J Cancer Res Clin Oncol. 136:1755–1759.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Schil PE, Bass P, Gaafar R, et al:
Trimodality therapy for malignant pleural mesothelioma: results
from an EORTC phase II multicentre trial. Eur Respir J.
36:1362–1369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Dale TC: Signal transduction by the Wnt
family of ligands. Biochem J. 329:209–223. 1998.
|
|
6.
|
You Z, Saims D, Chen S, et al: Wnt
signaling promotes oncogenic transformation by inhibiting
c-Myc-induced apoptosis. J Cell Biol. 157:429–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Huang C, Liu D, Masuya D, et al: MRP-1/CD9
gene transduction downregulates Wnt signal pathways. Oncogene.
23:7475–7483. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Huang C, Liu D, Ishikawa S, et al: Wnt1
overexpression promotes tumour progression in non-small cell lung
cancer. Eur J Cancer. 44:2680–2688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Huang C, Liu D, Nakano J, et al: Wnt5a
expression is associated with the tumor proliferation and the
stromal vascular endothelial growth factor-A expression in
non-small cell lung cancer. J Clin Oncol. 23:8765–8773. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Chen G, Shukeir N, Potti A, et al:
Up-regulation of Wnt-1 and β-catenin production in patients with
advanced metastatic prostate carcinoma: potential pathogenetic and
prognostic implications. Cancer. 101:1345–1356. 2004.
|
|
11.
|
Zhang WM, Lo Muzio L, Rubini C and Yan G:
Effect of WNT-1 on β-catenin expression and its relation to Ki-67
and tumor differentiation in oral squamous cell carcinoma. Oncol
Rep. 13:1095–1099. 2005.
|
|
12.
|
Lee A, Raz DJ, He B and Jablons DM: Update
on the molecular biology of malignant mesothelioma. Cancer.
109:1454–1461. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Kim PJ, Plescia J, Clevers H, Fearon ER
and Altieri DC: Survivin and molecular pathogenesis of colorectal
cancer. Lancet. 362:205–209. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Ma H, Nguyen C, Lee KS and Kahn M:
Differential roles for the coactivators CBP and p300 on
TCF/β-catenin-mediated survivin gene expression. Oncogene.
24:3619–3631. 2005.PubMed/NCBI
|
|
15.
|
He TC, Sparks AB, Rago C, et al:
Identification of c-MYC as a target of the APC pathway. Science.
281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Husain AN, Colby TV, Ordonez NG, et al:
Guidelines for pathologic diagnosis of malignant mesothelioma. Arch
Pathol Lab Med. 133:1317–1331. 2009.PubMed/NCBI
|
|
17.
|
Attanoos RL and Gibbs AR: Pathology of
malignant mesothelioma. Histopathology. 30:403–418. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Nakano J, Huang C, Liu D, et al: The
clinical significance of splice variants and subcellular
localization of survivin in non-small cell lung cancer. Br J
Cancer. 98:1109–1117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Katoh M, Kirikoshi H, Terasaki H and
Shiokawa K: WNT2B2 mRNA, up-regulated in primary gastric cancer, is
a positive regulator of the WNT-beta-catenin-TCF signaling pathway.
Biochem Biophys Res Commun. 289:1093–1098. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Zhang X, Gaspard JP and Chung DC:
Regulation of vascular endothelial growth factor by the Wnt and
K-ras pathways in colonic neoplasia. Cancer Res. 61:6050–6054.
2001.PubMed/NCBI
|
|
21.
|
Lu CD, Altieri DC and Tanigawa N:
Expression of a novel anti-apoptosis gene, survivin, correlated
with tumor cell apoptosis and p53 accumulation in gastric
carcinomas. Cancer Res. 58:1808–1812. 1998.PubMed/NCBI
|
|
22.
|
Kawasaki H, Altieri DC, Lu CD, Toyoda M,
Tenjo T and Tanigawa N: Inhibition of apoptosis by survivin
predicts shorter survival rates in colorectal cancer. Cancer Res.
58:5071–5074. 1998.PubMed/NCBI
|
|
23.
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Li F, Ambrosini G, Chu EY, et al: Control
of apoptosis and mitotic spindle checkpoint by survivin. Nature.
396:580–584. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Adams RR, Carmena M and Earnshaw WC:
Chromosomal passengers and the (aurora) ABCs of mitosis. Trends
Cell Biol. 11:49–54. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Martinez A, Bellosillo B, Bosch F, et al:
Nuclear survivin expression in mantle cell lymphoma is associated
with cell proliferation and survival. Am J Pathol. 164:501–510.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Shinohara ET, Gonzalez A, Massion PP, et
al: Nuclear survivin predicts recurrence and poor survival in
patients with resected nonsmall cell lung carcinoma. Cancer.
103:1685–1692. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Brennan DJ, Rexhepaj E, O’Brien SL, et al:
Altered cytoplasmicto nuclear ratio of survivin is a prognostic
indicator in breast cancer. Clin Cancer Res. 14:2681–2689. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Dang CV, Resar LM, Emison E, et al:
Function of the c-Myc oncogenic transcription factor. Exp Cell Res.
253:63–77. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Yang G, Timme TL, Frolov A, Wheeler TM and
Thompson TC: Combined c-Myc and caveolin-1 expression in human
prostate carcinoma predicts prostate carcinoma progression. Cancer.
103:1186–1194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lu D, Kadota K, Ueno M, Nakashima N,
Yokomise H and Huang CL: Adenoviral vector expressing short hairpin
RNA targeting Wnt2B has an effective antitumour activity against
Wnt2B2-overexpressing tumours. Eur J Cancer. Jun 4–2011, (Epub
ahead of print).
|
|
32.
|
Rao DD, Vorhies JS, Senzer N, et al: siRNA
vs. shRNA: similarities and differences. Adv Drug Deliv Rev.
61:746–759. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Ma B, Zhang S, Jiang H, Zhao B and Lv H:
Lipoplex morphologies and their influences on transfection
efficiency in gene delivery. J Control Release. 123:184–194. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Watanabe Y, Kojima T, Kagawa S, et al: A
novel translational approach for human malignant pleural
mesothelioma: heparanase-assisted dual virotherapy. Oncogene.
29:1145–1154. 2010. View Article : Google Scholar : PubMed/NCBI
|
